Waning antibody levels after COVID-19 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors, Hong Kong, April 2020 to October 2021-Reference-Cited by-同舟云学术

Waning antibody levels after COVID-19 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors, Hong Kong, April 2020 to October 2021

Published:2022-01-13 Issue:2 Volume:27 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Kwok Shirley LL¹²,Cheng Samuel MS³⁴²,Leung Jennifer NS⁵,Leung Kathy¹²^ORCID,Lee Cheuk-Kwong⁵,Peiris JS Malik³⁴²,Wu Joseph T¹²

Affiliation:

1. Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong Special Administrative Region, China

2. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China

3. Centre for Immunology and Infection (C2i), Hong Kong Science Park, Hong Kong Special Administrative Region, China

4. HKU-Pasteur Research Pole, School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China

5. Hong Kong Red Cross Blood Transfusion Service, Hospital Authority, Hong Kong Special Administrative Region, China

Abstract

The mRNA vaccine Comirnaty and the inactivated vaccine CoronaVac are both available in Hong Kong’s COVID-19 vaccination programme. We observed waning antibody levels in 850 fully vaccinated (at least 14 days passed after second dose) blood donors using ELISA and surrogate virus neutralisation test. The Comirnaty-vaccinated group’s (n = 593) antibody levels remained over the ELISA and sVNT positive cut-offs within the first 6 months. The CoronaVac-vaccinated group’s (n = 257) median antibody levels began to fall below the cut-offs 4 months after vaccination.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference17 articles.

1. The Government of Hong Kong Special Administrative Region. Hong Kong vaccination dashboard. Hong Kong: The Government of Hong Kong Special Administrative Region; 2021. [Accessed: 5 Dec 2021]. Available from: https://www.covidvaccine.gov.hk/en/dashboard/

2. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020.;Perera;Euro Surveill,2020

3. Evaluation of a SARS-CoV-2 surrogate virus neutralization test for detection of antibody in human, canine, cat, and hamster sera.;Perera;J Clin Microbiol,2021

4. China’s COVID vaccines have been crucial - now immunity is waning.;Mallapaty;Nature,2021

5. European Medicines Agency. COVID-19 vaccines: under evaluation. Amsterdam: EMA; 2022. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-under-evaluation#covid-19-vaccines-under-rolling-review-section.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety, Immunogenicity, and Effectiveness of Chinese-Made COVID-19 Vaccines in the Real World: An Interim Report of a Living Systematic Review;Vaccines;2024-07-16

2. High SARS-CoV-2 infection rate in children unvaccinated with COVID-19 vaccine in Changzhou, China, shortly after lifting zero-COVID-19 policy in December 2022;BMC Infectious Diseases;2024-06-05

3. Antibody longevity and waning following COVID-19 vaccination in a 1-year longitudinal cohort in Bangladesh;Scientific Reports;2024-05-20

4. Phylogenetic insights into the genetic legacies of Hungarian-speaking communities in the Carpathian Basin;Scientific Reports;2024-05-20

5. Epidemiological characteristics of first-time SARS-CoV-2 Omicron infection among hospital staff in Chengdu, China;2024-04-19